Skip to main content
SpringerLink
Log in

Oral sirolimus with bare metal stenting pays off

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Rodriguez A, Maree A, Tarragona S, Fernandez-Pereira C, Rodriguez-Graniilo AM, Rodriguez-Granillo GA, Santaera O, Mieres J, Kukreja N, Antoniucci D, Palacios IF, Serruys PW.Percutaneous coronary intervention with bare metal stents and oral sirolimus has comparable safety and efficacy to treatment with drug eluting stents but with significant cost saving: long term follow up results from the randomized, controlled ORAR III (Oral Rapamycin in Argentina) Study. 81st Annual Scientific Sessions of the American Heart Association: 1051 abstr. 6032, 8 Nov 2008. Available from: URL: http://scientificsessions.americanheart.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oral sirolimus with bare metal stenting pays off. Pharmacoecon. Outcomes News 568, 8 (2008). https://doi.org/10.2165/00151234-200805680-00020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805680-00020

Keywords

Search

Navigation